Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares gapped down prior to trading on Friday after Wedbush downgraded the stock from an outperform rating to a neutral rating. The stock had previously closed at $70.87, but opened at $71.99. Wedbush now has a $75.00 price target on the stock, down from their previous price target of $80.00. Ultragenyx Pharmaceutical shares last traded at $69.63, with a volume of 932,440 shares.
Several other analysts have also recently commented on the stock. Cowen and Company reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 17th. Canaccord Genuity reiterated a “buy” rating and issued a $100.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Thursday, March 23rd. Jefferies Group LLC reiterated a “buy” rating and issued a $109.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 17th. Zacks Investment Research cut shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, January 4th. Finally, Piper Jaffray Companies restated a “neutral” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, March 23rd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the company’s stock. Ultragenyx Pharmaceutical has an average rating of “Buy” and an average target price of $83.14.
In other Ultragenyx Pharmaceutical news, insider Theodore Alan Huizenga sold 2,500 shares of the company’s stock in a transaction dated Thursday, March 9th. The shares were sold at an average price of $86.34, for a total value of $215,850.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Shalini Sharp sold 12,000 shares of the company’s stock in a transaction dated Monday, February 27th. The stock was sold at an average price of $80.14, for a total transaction of $961,680.00. Following the completion of the transaction, the chief financial officer now owns 63,887 shares in the company, valued at $5,119,904.18. The disclosure for this sale can be found here. Insiders sold a total of 26,500 shares of company stock worth $2,258,730 over the last 90 days. Insiders own 10.10% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in RARE. Pacer Advisors Inc. increased its position in Ultragenyx Pharmaceutical by 9.4% in the third quarter. Pacer Advisors Inc. now owns 2,237 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 192 shares in the last quarter. Turner Investments LLC acquired a new position in Ultragenyx Pharmaceutical during the fourth quarter worth about $176,000. A.R.T. Advisors LLC acquired a new position in Ultragenyx Pharmaceutical during the fourth quarter worth about $239,000. BlackRock Inc. increased its position in Ultragenyx Pharmaceutical by 6.8% in the third quarter. BlackRock Inc. now owns 4,244 shares of the biopharmaceutical company’s stock worth $301,000 after buying an additional 271 shares in the last quarter. Finally, Rothschild Asset Management Inc. increased its position in Ultragenyx Pharmaceutical by 17.4% in the third quarter. Rothschild Asset Management Inc. now owns 5,600 shares of the biopharmaceutical company’s stock worth $397,000 after buying an additional 830 shares in the last quarter. Hedge funds and other institutional investors own 96.35% of the company’s stock.
The firm’s market cap is $2.51 billion. The stock’s 50-day moving average price is $72.59 and its 200-day moving average price is $72.33.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, February 16th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.72) by $0.03. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.05 million. Ultragenyx Pharmaceutical’s revenue for the quarter was up 4900.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.42) earnings per share. Analysts predict that Ultragenyx Pharmaceutical Inc will post ($7.07) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.chaffeybreeze.com/2017/04/21/ultragenyx-pharmaceutical-inc-rare-shares-gap-down-after-analyst-downgrade-updated-updated.html.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.